Arsenic trioxide-induced cardiotoxicity: insights into the oxidative stress-inflammation positive feedback loop, translational biomarkers and targeted cardioprotective strategies— a narrative review
- 1Graduate School, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China
- 2School of Basic Medical Science, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China
Abstract
Arsenic trioxide (ATO) is a first-line chemotherapeutic agent that achieves a complete remission rate above 90% in newly diagnosed acute promyelocytic leukemia, with indications expanding to multiple hematological malignancies and solid tumors. However, dose-dependent cardiotoxicity—manifesting as acute QTc prolongation and malignant arrhythmia, as well as chronic myocardial hypertrophy, interstitial fibrosis and progressive heart failure—remains a critical clinical barrier that limits its therapeutic window, and no approved targeted cardioprotective regimens are currently available in clinical practice. This narrative Mini Review proposes an integrated mechanistic framework centered on the oxidative stress–inflammation positive feedback loop, which complements the conventional view of two independent pathogenic pathways. In this framework, ATO-induced mitochondrial dysfunction and impaired Nrf2 antioxidant defense initiate oxidative stress as the upstream trigger; ROS subsequently drives inflammatory activation via NF-κB and NLRP3 inflammasome pathways, while sustained inflammation in turn aggravates oxidative damage by suppressing Nrf2 activity and disrupting mitochondrial homeostasis. This proposed self-amplifying loop exhibits spatiotemporal heterogeneity. It appears incompletely established in acute electrophysiological injury, but may serve as a potential mechanistic contributor to chronic structural remodeling. Based on this framework, this work summarizes dual-target cardioprotective strategies that preserve ATO’s anti-tumor efficacy, and evaluates translational biomarkers for early risk stratification. Collectively, this review provides a mechanistic foundation for precision cardioprotection and clinical safety optimization of ATO-based chemotherapy.
Related
- Interleukin-Driven Inflammation and Cardiovascular Risk in People Living with HIV: Mechanisms, Biomarkers, and Emerging Preventive Strategies
- Inflammation and wound healing: a comprehensive overview of mechanisms, therapeutic strategies, and translational perspectives
- Targeting STAT3 to Modulate the Effectiveness of Cardioprotective Conditioning Strategies Against Myocardial Ischemia-Reperfusion Injury in Subjects With Diabetic Cardiomyopathy.
- Nanodelivery of Brucine in Myocardial Ischemia-Reperfusion Injury: Mitochondrial PANoptosis, Cardiotoxicity, and Translational Barriers.
- Polyphenols and Flavonoids in microRNA-Regulated Pathways of Doxorubicin-Induced Cardiotoxicity: Mechanistic Evidence, Biomarker Potential and Translational Gaps
BibTeX
@article{wu2026arsenic,
title = {{Arsenic trioxide-induced cardiotoxicity: insights into the oxidative stress-inflammation positive feedback loop, translational biomarkers and targeted cardioprotective strategies— a narrative review}},
author = {Haiyan Wu and Jian Lv and Xiaoyang Hu},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1954263},
url = {https://doi.org/10.3389/fonc.2026.1954263},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Arsenic trioxide-induced cardiotoxicity: insights into the oxidative stress-inflammation positive feedback loop, translational biomarkers and targeted cardioprotective strategies— a narrative review
AU - Haiyan Wu
AU - Jian Lv
AU - Xiaoyang Hu
PY - 2026
DA - 2026/10/12
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1954263
UR - https://doi.org/10.3389/fonc.2026.1954263
AB - Arsenic trioxide (ATO) is a first-line chemotherapeutic agent that achieves a complete remission rate above 90% in newly diagnosed acute promyelocytic leukemia, with indications expanding to multiple hematological malignancies and solid tumors. However, dose-dependent cardiotoxicity—manifesting as acute QTc prolongation and malignant arrhythmia, as well as chronic myocardial hypertrophy, interstitial fibrosis and progressive heart failure—remains a critical clinical barrier that limits its therapeutic window, and no approved targeted cardioprotective regimens are currently available in clinical practice. This narrative Mini Review proposes an integrated mechanistic framework centered on the oxidative stress–inflammation positive feedback loop, which complements the conventional view of two independent pathogenic pathways. In this framework, ATO-induced mitochondrial dysfunction and impaired Nrf2 antioxidant defense initiate oxidative stress as the upstream trigger; ROS subsequently drives inflammatory activation via NF-κB and NLRP3 inflammasome pathways, while sustained inflammation in turn aggravates oxidative damage by suppressing Nrf2 activity and disrupting mitochondrial homeostasis. This proposed self-amplifying loop exhibits spatiotemporal heterogeneity. It appears incompletely established in acute electrophysiological injury, but may serve as a potential mechanistic contributor to chronic structural remodeling. Based on this framework, this work summarizes dual-target cardioprotective strategies that preserve ATO’s anti-tumor efficacy, and evaluates translational biomarkers for early risk stratification. Collectively, this review provides a mechanistic foundation for precision cardioprotection and clinical safety optimization of ATO-based chemotherapy.
SN - 2234-943X
ER -